Airsculpt Technologies, Inc.
AIRS Nasdaq Services-Offices & Clinics Of Doctors Of Medicine Financials FY2019βFY2025
Last close Β· Oct 23, 2026
$1.20
4.0%What Airsculpt Technologies, Inc. does
No business description yet.
- Legal name
- Airsculpt Technologies, Inc.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K Β· Mar 31, 2026
- Accession Β· CIK
- 0001870940-26-000011
0001870940
Revenue and margins
Airsculpt Technologies, Inc. had $152M of revenue in fiscal 2025, down 15.8% on the year before.
Net income and earnings per share
Loss periods are shown in red.
Returns on capital
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Cash flow
Free cash flow was $0.7M in fiscal 2025, 0.5% of revenue. Cash from operations minus capital spending.
Dividends, buybacks and share count
Airsculpt Technologies, Inc. returned $0.0M to shareholders in fiscal 2025, 0% of free cash flow. The diluted share count rose 4.8%.
Balance sheet
Cash, debt and the ratios that show how comfortably Airsculpt Technologies, Inc. can carry it.
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | $25.3M | $9.6M | $10.3M | $8.2M | $8.4M |
| Debt incl. finance leases | $82.6M | $83.5M | $71.6M | $69.7M | $56.0M |
| Net debt / EBITDA | 2.6x | 21.0x | 3.1x | 6.0x | 39.0x |
| Debt / equity | 1.0x | 1.2x | 0.9x | 0.9x | 0.6x |
| Interest coverage | 3.2x | β0.7x | 1.5x | β0.3x | β1.9x |
| Current ratio | 1.8x | 0.7x | 0.8x | 0.6x | 0.6x |
| Quick ratio | 1.8x | 0.7x | 0.8x | 0.6x | 0.6x |
| Total assets | $201M | $201M | $204M | $213M | $187M |
| Total liabilities | $117M | $130M | $120M | $135M | $99.6M |
| Shareholders' equity | $83.5M | $70.8M | $82.7M | $78.2M | $87.7M |
| Net debt (β = net cash) | $57.3M | $73.9M | $61.4M | $61.5M | $47.6M |
Insider trades
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. 'Plan' marks trades under a pre-arranged Rule 10b5-1 plan.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$0.0M
0 insiders
Of sales under plans
β
$0.0M
No open-market insider trades in the last 12 months.
Piotroski F-score
Nine pass/fail tests of profitability, funding and efficiency. 8β9 is strong, 0β2 weak.
| Test | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|
| Net income is positive | β | β | β | β | β | β | β |
| Cash from operations is positive | β | β | β | β | β | β | β |
| Return on assets rose | β | β | β | β | β | β | β |
| Cash from operations exceeds net income | β | β | β | β | β | β | β |
| Debt fell relative to assets | β | β | β | β | β | β | β |
| Current ratio rose | β | β | β | β | β | β | β |
| Share count didn't rise | β | β | β | β | β | β | β |
| Gross margin rose | β | β | β | β | β | β | β |
| Revenue rose relative to assets | β | β | β | β | β | β | β |
| F-score | β / 3 | β / 3 | 6 / 7 | 3 / 8 | 6 / 8 | 3 / 8 | 3 / 8 |
| Accruals ratio | β | β3.6% | β8.5% | β19.5% | β13.9% | β9.3% | β7.4% |
| Altman Z'' | β | β | 1.70 | β0.01 | 0.59 | β0.25 | β0.63 |
7 years of figures
US$ millions unless stated. Hover a ratio's name for its definition.
| Fiscal year | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | $41.2M | $62.8M | $133M | $169M | $196M | $180M | $152M |
| Operating income | $0.7M | $10.0M | $15.8M | β$4.5M | $9.7M | β$1.6M | β$11.6M |
| Interest expense | $2.9M | $2.5M | $4.9M | $6.8M | $6.5M | $6.2M | $6.1M |
| Pretax income | β$2.2M | $7.6M | $10.9M | β$11.3M | $3.2M | β$7.8M | β$17.6M |
| Income tax | $0.0M | $0.0M | $0.3M | $3.4M | $7.5M | $0.2M | β$6.0M |
| Net income | β$2.2M | $7.6M | $10.6M | β$14.7M | β$4.2M | β$8.0M | β$11.7M |
| Net income to common | β | β | $10.6M | β$14.7M | β$4.2M | β$8.0M | β$11.7M |
| Diluted EPS | β | β | β$0.01 | β$0.26 | β$0.08 | β$0.14 | β$0.19 |
| Diluted shares | β | β | 0.06B | 0.06B | 0.06B | 0.06B | 0.06B |
| Cash flow | |||||||
| Cash from operations | $4.9M | $14.0M | $26.6M | $24.4M | $24.0M | $11.4M | $3.1M |
| Capital expenditure | $4.4M | $3.7M | $7.1M | $12.9M | $9.9M | $14.0M | $2.4M |
| Free cash flow | $0.5M | $10.3M | $19.5M | $11.5M | $14.0M | β$2.7M | $0.7M |
| Depreciation and amortization | $5.0M | $5.6M | $6.6M | $8.1M | $10.3M | $11.9M | $12.8M |
| Stock-based compensation | $0.3M | $0.3M | $7.2M | $29.5M | $18.2M | $3.8M | $2.3M |
| Dividends paid | β | $0.0M | $0.0M | $23.2M | $0.4M | $0.3M | $0.0M |
| Dividends and buybacks | β | $0.0M | $0.0M | $23.2M | $0.4M | $0.3M | $0.0M |
| Balance sheet | |||||||
| Cash and short-term investments | $5.1M | $10.4M | $25.3M | $9.6M | $10.3M | $8.2M | $8.4M |
| Total debt | β | $32.5M | $82.6M | $83.5M | $71.6M | $69.7M | $56.0M |
| Current assets | β | $11.6M | $29.4M | $16.7M | $16.0M | $17.1M | $15.5M |
| Current liabilities | β | $9.5M | $16.4M | $22.3M | $20.3M | $28.9M | $27.9M |
| Property and equipment, net | β | $7.1M | $13.6M | $24.2M | $28.9M | $37.5M | $27.8M |
| Goodwill | β | $81.7M | $81.7M | $81.7M | $81.7M | $81.7M | $81.7M |
| Intangible assets | β | $60.6M | $55.9M | $51.1M | $46.3M | $41.6M | $36.8M |
| Total assets | β | $180M | $201M | $201M | $204M | $213M | $187M |
| Total liabilities | β | $55.9M | $117M | $130M | $120M | $135M | $99.6M |
| Shareholders' equity | β | β | $83.5M | $70.8M | $82.7M | $78.2M | $87.7M |
| Margins | |||||||
| Operating margin | 1.6% | 16.0% | 11.8% | β2.7% | 5.0% | β0.9% | β7.6% |
| EBITDA margin | 13.6% | 25.0% | 16.8% | 2.1% | 10.2% | 5.7% | 0.8% |
| Net margin | β5.4% | 12.1% | 7.9% | β8.7% | β2.2% | β4.4% | β7.7% |
| FCF margin | 1.2% | 16.4% | 14.6% | 6.8% | 7.2% | β1.5% | 0.5% |
| Returns | |||||||
| Return on capital | β | β | 10.9% | β2.5% | 4.4% | β0.9% | β6.7% |
| Return on capital employed | β | 5.9% | 8.6% | β2.5% | 5.3% | β0.9% | β7.3% |
| Return on equity | β | β | 12.6% | β19.0% | β5.5% | β10.0% | β14.1% |
| Return on assets | β | 4.2% | 5.6% | β7.3% | β2.1% | β3.8% | β5.8% |
| Growth | |||||||
| Revenue growth | β | 52.2% | 112.4% | 26.6% | 16.1% | β7.9% | β15.8% |
| Net income growth | β | β | 39.3% | β239.1% | β | β | β |
| FCF growth | β | 1,957.7% | 90.1% | β40.9% | 21.8% | β118.9% | β |
| Share count change | β | β | β | 0.1% | 2.0% | 1.6% | 4.8% |
| Financial health | |||||||
| Net debt / EBITDA | β | 1.4x | 2.6x | 21.0x | 3.1x | 6.0x | 39.0x |
| Debt / equity | β | β | 1.0x | 1.2x | 0.9x | 0.9x | 0.6x |
| Interest coverage | 0.2x | 4.1x | 3.2x | β0.7x | 1.5x | β0.3x | β1.9x |
| Current ratio | β | 1.2x | 1.8x | 0.7x | 0.8x | 0.6x | 0.6x |
| Quick ratio | β | 1.2x | 1.8x | 0.7x | 0.8x | 0.6x | 0.6x |
| Capital allocation | |||||||
| Capex / revenue | 10.8% | 5.9% | 5.3% | 7.7% | 5.1% | 7.8% | 1.6% |
| Stock comp / revenue | 0.8% | 0.5% | 5.4% | 17.5% | 9.3% | 2.1% | 1.5% |
| Payouts / FCF | β | 0.0% | 0.0% | 200.9% | 2.7% | β | 0.0% |
| Quality scores | |||||||
| Piotroski F-score | β | β | 6.0 | 3.0 | 6.0 | 3.0 | 3.0 |
| Altman Z'' | β | β | 1.7 | β0.0 | 0.6 | β0.2 | β0.6 |
| Accruals ratio | β | β3.6% | β8.5% | β19.5% | β13.9% | β9.3% | β7.4% |
Source: SEC EDGAR XBRL filings (CIK 0001870940). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only β not investment advice. Check the original filings before relying on any figure.